prikaz prve stranice dokumenta Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
  Preuzmi
PDF 289.29 KB
Znanstveni rad - Izvorni znanstveni rad
Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
Multiple Sclerosis and Related Disorders, 17 (2017); 151-153. https://doi.org/10.1016/j.msard.2017.07.019
Šega-Jazbec, Saša; Barun, Barbara; Horvat Ledinek, Alenka; Fabekovac, Višnja; Krbot Skorić, Magdalena; Habek, Mario

Citirajte ovaj rad

Šega Jazbec, S., Barun, B., Horvat Ledinek, A., Fabekovac, V., Krbot Skorić, M. i Habek, M. (2017). Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 17., 151-153. doi: 10.1016/j.msard.2017.07.019

Šega Jazbec, Saša, et al. "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis." Multiple Sclerosis and Related Disorders, vol. 17, 2017, str. 151-153. https://doi.org/10.1016/j.msard.2017.07.019

Šega Jazbec, Saša, Barbara Barun, Alenka Horvat Ledinek, Višnja Fabekovac, Magdalena Krbot Skorić i Mario Habek. "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis." Multiple Sclerosis and Related Disorders 17 (2017): 151-153. https://doi.org/10.1016/j.msard.2017.07.019

Šega Jazbec, S., et al. (2017) 'Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis', Multiple Sclerosis and Related Disorders, 17, str. 151-153. doi: 10.1016/j.msard.2017.07.019

Šega Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek M. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders [Internet]. 10.2017. [pristupljeno 16.04.2024.];17:151-153. doi: 10.1016/j.msard.2017.07.019

S. Šega Jazbec, B. Barun, A. Horvat Ledinek, V. Fabekovac, M. Krbot Skorić i M. Habek, "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis", Multiple Sclerosis and Related Disorders, vol. 17, str. 151-153, Listopad 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:902880. [Citirano: 16.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:902880
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
AutorSaša Šega-Jazbec
AutorBarbara Barun
AutorAlenka Horvat Ledinek
AutorVišnja Fabekovac
AutorMagdalena Krbot Skorić
AutorMario Habek
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVE: Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols. ----- METHODS: This was retrospective chart review of 38 consecutive MS patients who were treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, University Hospital Center Zagreb, Croatia and Department of Neurology, University Medical Center Ljubljana, Slovenia. ----- RESULTS: Seventeen patients (44.7%) did not experience IARs. Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions and they were most frequent on Day 5 and Day 1, respectively. We have observed significant differences in the occurrence of fever (p = 0.005) depending on the site of alemtuzumab administration which could be explained by different antipyretics used; fever was absent in the Slovenian cohort because high dose intravenous metamizole was administered. Two out of 9 treatment naïve, and 19 out of 29 patients who previously received immunomodulatory treatment had IARs (χ2 = 5.208, p = 0.022). ----- CONCLUSION: Modified premedication scheme consisting of 1g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaMultiple Sclerosis and Related Disorders
Brojčani podacivol. 17, str. 151-153
p-ISSN2211-0348
DOIhttps://doi.org/10.1016/j.msard.2017.07.019
URN:NBNurn:nbn:hr:105:902880
Datum objave publikacije2017-10
URL dokumentahttps://doi.org/10.1016/j.msard.2017.07.019
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:17:28